Daily Archives: April 2, 2014

How we’ve applied N-of-8® to uncover new product concepts

Using N-of-8 for new brand concepts can generate high potential new product and service ideas. The “open innovation” approach has long been taken by successful innovators, but it remains difficult – because the “not invented here” syndrome is seductive and stubborn to overcome. Going outside for ideas is much more complex than internally, because so many external groups of stakeholders may offer insights of value.  Here are several ways we have applied the N-of-8 tool to uncover new product concepts: 8 Individual Interviews – you can begin quickly and easily this by reaching out and speaking with people.  Many customers, […]

4-part model to create brand CHEMistry with customers

Here’s a summary of the talk I gave to an Asia-Pacific sales and marketing conference in Cebu, Philippines. Life science and technology brands make personal connections with consumers beyond that of many other products. This connection goes beyond mere advertising. Marketers must create brands, experiences, and relationships that embody the intricate balance between the research customer’s needs and the company’s business objectives. This presentation offers a creative innovation model to help the customers accelerate their research – and help the company accelerate sales. Presenting C.H.E.M. – our tool to truly create brand CHEMistry with customers. C = Connect Purpose: Fit […]

3 benefits of drug repositioning – and the application of Strategic GPS®

A number of studies have shown that in the last 10 to 15 years, while R&D spending has steadily increased, the number of drugs making it to the market has not followed pace.  That’s why the advantages of drug positioning hold such allure. The key advantage of the drug repositioning approach is that it reduces the time, cost, and risk compared with de novo development. As well as providing an advantage to companies, it also provides an advantage to patients, because it reduces the overall cost by rescuing the investment in failed drugs and makes safer and more effective drugs […]